Meridian Bioscience (VIVO) 19.49 $VIVO Meridian

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Meridian Bioscience (VIVO) 19.49 $VIVO

Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance
GlobeNewswire - Thu Jul 28, 7:02AM CDT
GENERAL HIGHLIGHTS
VIVO: 19.49 (+0.13)

Look at Medical Product Earnings on Jul 28: BSX, RMD & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:59AM CDT
Medical is one of the seven broader sectors among the 16 Zacks sectors to report earnings growth this season.
BSX: 24.44 (+0.16), SRDX: 27.04 (-0.39), ZBH: 131.15 (+0.01), VIVO: 19.49 (+0.13), RMD: 69.58 (+0.70)

MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 118.86 (+0.89), LDRH: 36.98 (-0.02), MDT: 87.59 (-0.04), PAHC: 20.55 (-0.08), MLAB: 116.00 (+0.37), NUVA: 63.04 (+0.84), BSX: 24.44 (+0.16), BABY: 39.54 (+0.21), SNN: 33.30 (+0.01), JNJ: 125.16 (-0.07), DXCM: 92.50 (+0.27), GWPH: 95.22 (+0.90), RMD: 69.58 (+0.70), WOOF: 71.17 (-0.17), ABT: 45.10 (+0.35), VIVO: 19.49 (+0.13), MASI: 53.10 (+0.13), TMO: 159.09 (+0.25), CYH: 12.63 (-0.14), HTWR: 57.92 (-0.02), FEIC: 106.50 (+0.08), ISRG: 697.00 (+1.24), CFMS: 6.95 (-0.02), STE: 71.19 (+0.24), STJ: 83.37 (+0.33), XRAY: 64.15 (+0.11), HOLX: 38.98 (+0.49)

Bioline Launches New MyTaq(TM) Plant-PCR Kit
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq(TM) Plant-PCR Kit, the latest in the line of kits from Bioline for direct PCR. The MyTaq(TM) Plant-PCR Kit is the first of many products Bioline is bringing to the agricultural market to advance plant genetic research. Bioline is also developing new technologies to support Agribio companies in their quest to improve agriculturally important plants.
VIVO: 19.49 (+0.13)

Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GlobeNewswire - Thu Apr 28, 6:45AM CDT
GENERAL HIGHLIGHTS
VIVO: 19.49 (+0.13)

Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
Globe Newswire - Thu Apr 28, 1:00AM CDT
illumigene(R) Mycoplasma Direct provides fast and accurate results in less than 1 hour for immediate and targeted treatment
VIVO: 19.49 (+0.13)

Great Basin Announces Expansion of Executive Leadership
BusinessWire - Tue Apr 05, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today the expansion of the Company's leadership team with the appointment of Mike Blitz as vice president of U.S. sales, and the promotion of Sandra Nielsen to the position of senior vice president of sales and marketing. Previously, Ms. Nielsen served as the vice president of marketing and human resources and acting vice president of sales for Great Basin.
GBSN: 0.50 (+0.01), VIVO: 19.49 (+0.13), GBSNU: 16.22 (-0.28)

Upgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Tue Mar 29, 3:34AM CDT
Meridian Bioscience (NASDAQ:VIVO) was upgraded from Neutral to Buy at Hilliard Lyons today. The stock closed yesterday at $20.41 on volume of 288,000 shares, above average daily volume of 256,000. Meridian Bioscience, Inc. manufactures, markets, and distributes diagnostic test kits, purified reagents, and related products. The Company also offers bio- pharmaceutical enabling technologies. Meridian specializes in gastrointestinal and upper respiratory infections, serology, parasitology, and fungal disease diagnosis, as well as rare reagents and specialty biologicals.
VIVO: 19.49 (+0.13)

Meridian Bioscience Acquires Magellan Diagnostics, Inc.
GlobeNewswire - Thu Mar 24, 3:15PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.
VIVO: 19.49 (+0.13)

Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Tue Mar 22, 3:45AM CDT
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Long-Term Buy to Neutral at Hilliard Lyons today. The stock closed yesterday at $20.00 on volume of 376,000 shares, above average daily volume of 272,000. Meridian Bioscience share prices have moved between a 52-week high of $21.40 and a 52-week low of $16.60 and closed yesterday at 20% above that low price at $20.00 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.4%.
VIVO: 19.49 (+0.13)

Meridian Bioscience Q1 Earnings in Line, Sales Miss Mark
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 10:30AM CST
Shares of diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) rose 2% in the last three trading sessions following the company???s mixed first-quarter fiscal 2016 results.
VIVO: 19.49 (+0.13), STAA: 6.79 (-0.05), LMAT: 17.29 (+0.09), VASC: 46.18 (+0.31)

Meridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GlobeNewswire - Wed Jan 27, 6:30AM CST
GENERAL HIGHLIGHTS
VIVO: 19.49 (+0.13)

Meridian Bioscience and Lean Continuous Improvements, LLC Collaborate to Apply Lean Principles to Recent Launch of illumigene(R) Malaria
GlobeNewswire - Tue Jan 26, 11:03AM CST
Meridian Bioscience, Inc. announced today that the recent product transfer and launch of its innovative molecular test illumigene Malaria was accomplished on an accelerated schedule via a collaboration with Lean Continuous Improvements, LLC (LCI). The development and transfer of medical devices is a complicated and highly regulated process. Meridian recognized the need to streamline the tasks and activities required to move a new test from the product development phase through to final regulatory approval, and ultimately to our lab customers. Lean Continuous Improvements is a Cincinnati-based consulting firm that is expert in applying lean principles, in conjunction with project management, that minimize wasted time, that help facilitate conflict resolution and that increase the team's energy while maximizing product quality.
VIVO: 19.49 (+0.13)

New Malaria Test, illumigene(R) Malaria, Sets a New Gold Standard for Diagnosis
GlobeNewswire - Tue Jan 26, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for illumigene Malaria, a novel, highly accurate test developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal. The test is up to 80,000 times more sensitive at detecting the malaria parasite than conventional tests, potentially revolutionizing malaria diagnosis and establishing a new gold standard. Using innovative molecular LAMP technology, illumigene results are available in under one hour, and the test is easy to use as it does not rely on high level technical expertise. This is a major step forward for people with malaria as faster, more accurate diagnoses should lead to prompt treatment and better outcomes. illumigene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company's global distribution network.
VIVO: 19.49 (+0.13)

High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 45.10 (+0.35), MYGN: 31.32 (+0.34), VIVO: 19.49 (+0.13), A: 47.83 (-0.28), DHR: 81.49 (+0.05), ABAX: 49.54 (+0.08), DGX: 86.23 (-0.13), TRIB: 13.02 (+0.19), HOLX: 38.98 (+0.49)

Global Point of Care (POC) Pregnancy and Fertility Testing Market Report 2015
M2 - Tue Jan 19, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/d22vw2/poc_pregnancy_and) has announced the addition of the "POC Pregnancy and Fertility Testing Market" report to their offering. The female reproductive system is complex both in structure and in function. From birth to senescence, the organs of the female reproductive system function in concert with each other, with the brain, and with other endocrine organs. This integrated functioning constitutes some of the most intricate and elegant processes of the human body. Because the functioning of the female reproductive system has an enormous impact on the life of the individual women, increasing importance is placed on the active involvement of women in understanding their own health care needs such as determination of pregnancy and fertility. Point of care (POC) testing, diagnostic tests performed at or near the site where a patient is located, may be performed by laboratory personnel but are often performed by non-laboratory personnel, including patients themselves (self-testing). The menu for POC testing includes pregnancy and fertility testing. Point of Care (POC) Pregnancy and Fertility Testing Market examines the testing market for these segments, including: - 2014 Pregnancy and Fertility CLIA Waivers - Global POC Pregnancy and Fertility Testing Market Analysis, 2012-2019 - POC Pregnancy and Fertility Self-Testing Market Analysis, 2014 and 2019 - POC Pregnancy and Fertility Professional Testing Market Analysis, 2014 and 2019 - Global POC Pregnancy and Fertility Testing Market Revenues and Market Share of Leading Suppliers, 2014 The professional sector is made up of tests used in hospitals, physician offices and clinics. The over-the-counter (OTC) sector for pregnancy and ovulation (LH) includes tests available in pharmacies and other retail establishments. Both market segments are expected to grow over the report's forecast period. Many companies are involved in the development and/or marketing of POC pregnancy and fertility testing products. Among the top and/or innovative competitors discussed within the Corporate Profiles are firms that maintain leading positions in the market such as: - Alere - Church & Dwight - Insight Pharmaceuticals - Meridian - Quidel Key Topics Covered: ONE: EXECUTIVE SUMMARY - Overview of POC Testing - Pregnancy and Fertility - Size of the Market - POC Professional Testing - POC Pregnancy and Fertility Self-Testing - Growth of the Market - Leading Competitors TWO: POC PREGNANCY AND FERTILITY TESTING - Products - Market Size and Growth - POC Pregnancy and Fertility Self-Testing - POC Pregnancy and Fertility Professional Testing - Competitive Analysis - Product Innovation THREE: CORPORATE PROFILES - Alere Inc - Ani Biotech Oy - Beckman Coulter, Inc - bioMerieux SA - Cen-Med Enterprises, Inc. - Church & Dwight Co., Inc - EKF Diagnostics GmbH - EKLA Corporation - Insight Pharmaceuticals LLC - Meridian BioScience, Inc - Opko Health, Inc - Polymed Therapeutics Inc. - Polymedco, Inc - Quidel Corporation - Radiometer Medical ApS - Ramco Laboratories, Inc. - Roche Diagnostics Corporation - Siemens Healthcare - Stanbio Laboratory - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/d2...gnancy_and
CHD: 98.17 (-0.07), VIVO: 19.49 (+0.13), OPK: 9.93 (-0.02), TRIB: 13.02 (+0.19), ALR: 37.18 (-0.32)

Meridian Bioscience at 52-Week High on Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Dec 30, 12:10PM CST
Shares of Meridian Bioscience Inc. (VIVO) rallied to a new 52-week high of $20.92 on Dec 29 and closed a tad bit lower at $20.76.
ICUI: 117.15 (+0.39), INSY: 15.77 (+0.12), NXTM: 22.25 (+0.14), VIVO: 19.49 (+0.13)

Meridian Bioscience Up 12.0% Since SmarTrend Uptrend Call (VIVO)
Comtex SmarTrend(R) - Thu Dec 24, 5:20PM CST
SmarTrend identified an Uptrend for Meridian Bioscience (NASDAQ:VIVO) on October 23rd, 2015 at $18.32. In approximately 2 months, Meridian Bioscience has returned 11.98% as of today's recent price of $20.51.
VIVO: 19.49 (+0.13)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 212

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 375

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 238

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 262

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 377

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 192

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

APT Miner Mobile App Revolutionizes Cloud Mining Experience

Updated Category News Views 352

APT Miner Mobile App: A New Era in Cryptocurrency Mining APT Miner has launched a groundbreaking mobile application that opens the door to easy cryptocurrency mining for everyone. With this new app, users can seamlessly engage in mining operations from their mobile devices, without the need for technical expertise or complicated setups. The platform caters to a wide range...

Continue Reading
Investors Urged to Act Before September Deadline in Alto Case

Updated Category News Views 233

Important Announcement for Alto Neuroscience Investors In a recent advisory, investors of Alto Neuroscience, Inc. (NYSE: ANRO) are being urged to secure legal counsel as the deadline for a pivotal class action lawsuit approaches. The deadline for lead plaintiffs to step forward is September 19, 2025, providing investors who are affected by a range of factors related to...

Continue Reading
Strategic Sale: McStarlite Co. Partners with Standex International

Updated Category News Views 244

Strategic Changes Ahead for McStarlite Co. In a significant move, Janes Capital Partners has announced its role as the exclusive advisor for McStarlite Co. in its acquisition by Standex International Corporation (NYSE:SXI). This partnership highlights Janes Capital Partners’ capability to navigate complex transactions in the aerospace sector. McStarlite Co.: A Leader in...

Continue Reading
Codis Accelerates Growth with 1315 Capital Investment

Updated Category News Views 185

Codis Secures Funding for Expansion Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK....

Continue Reading
A Decade of Growth: The Journey of an Investment in Guidewire

Updated Category News Views 174

The Growth Journey of Guidewire Software Guidewire Software (GWRE) has seen significant advancements in the last decade, marking an impressive annualized return of 17.03%. Over this period, it has outperformed the broader market by 4.38%, which speaks volumes about the company’s stability and growth potential. Understanding Guidewire’s Market Position With a current...

Continue Reading